These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Gubareva LV; Webster RG; Hayden FG Antimicrob Agents Chemother; 2001 Dec; 45(12):3403-8. PubMed ID: 11709315 [TBL] [Abstract][Full Text] [Related]
6. Influenza virus sialidase: a target for drug discovery. Kiefel MJ; von Itzstein M Prog Med Chem; 1999; 36():1-28. PubMed ID: 10818670 [No Abstract] [Full Text] [Related]
7. In vitro generation and characterisation of an influenza B variant with reduced sensitivity to neuraminidase inhibitors. Cheam AL; Barr IG; Hampson AW; Mosse J; Hurt AC Antiviral Res; 2004 Sep; 63(3):177-81. PubMed ID: 15451185 [TBL] [Abstract][Full Text] [Related]
8. Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en. Staschke KA; Colacino JM; Baxter AJ; Air GM; Bansal A; Hornback WJ; Munroe JE; Laver WG Virology; 1995 Dec; 214(2):642-6. PubMed ID: 8553569 [TBL] [Abstract][Full Text] [Related]
9. Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir. Buxton RC; Edwards B; Juo RR; Voyta JC; Tisdale M; Bethell RC Anal Biochem; 2000 May; 280(2):291-300. PubMed ID: 10790313 [TBL] [Abstract][Full Text] [Related]
11. Zanamivir. A potent and selective inhibitor of influenza A and B viruses. Aoki FY; Hayden FG Clin Pharmacokinet; 1999; 36 Suppl 1():v-ix. PubMed ID: 10429834 [No Abstract] [Full Text] [Related]
12. Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase. Watson KG; Cameron R; Fenton RJ; Gower D; Hamilton S; Jin B; Krippner GY; Luttick A; McConnell D; MacDonald SJ; Mason AM; Nguyen V; Tucker SP; Wu WY Bioorg Med Chem Lett; 2004 Mar; 14(6):1589-92. PubMed ID: 15006410 [TBL] [Abstract][Full Text] [Related]
13. The anti-influenza virus agent 4-GU-DANA (zanamivir) inhibits cell fusion mediated by human parainfluenza virus and influenza virus HA. Greengard O; Poltoratskaia N; Leikina E; Zimmerberg J; Moscona A J Virol; 2000 Dec; 74(23):11108-14. PubMed ID: 11070006 [TBL] [Abstract][Full Text] [Related]
14. Does the availability of a neuraminidase inhibitor impair influenza vaccination? A report from Austria. Kunze U; Groman E; Vymazal K; Hartl HK Vaccine; 2001 Feb; 19(15-16):1854. PubMed ID: 11345055 [No Abstract] [Full Text] [Related]
15. Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies. Barnett JM; Cadman A; Gor D; Dempsey M; Walters M; Candlin A; Tisdale M; Morley PJ; Owens IJ; Fenton RJ; Lewis AP; Claas EC; Rimmelzwaan GF; De Groot R; Osterhaus AD Antimicrob Agents Chemother; 2000 Jan; 44(1):78-87. PubMed ID: 10602727 [TBL] [Abstract][Full Text] [Related]
16. The interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2en. Blick TJ; Sahasrabudhe A; McDonald M; Owens IJ; Morley PJ; Fenton RJ; McKimm-Breschkin JL Virology; 1998 Jun; 246(1):95-103. PubMed ID: 9656997 [TBL] [Abstract][Full Text] [Related]
18. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir. Hurt AC; Barr IG; Hartel G; Hampson AW Antiviral Res; 2004 Apr; 62(1):37-45. PubMed ID: 15026200 [TBL] [Abstract][Full Text] [Related]
19. Selection of influenza A and B viruses for resistance to 4-guanidino-Neu5Ac2en in cell culture. Colacino JM; Laver WG; Air GM J Infect Dis; 1997 Aug; 176 Suppl 1():S66-8. PubMed ID: 9240698 [TBL] [Abstract][Full Text] [Related]